Asrar Alahmadi is an Oncology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 62 publications with 315 citations (h-index 8); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 W 10th Ave Fl 2
Columbus, OH 432101280
Telephone
614-293-5066Provider last certified this registry record 10 Jun 2025.
Clinical trials
- Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Sponsor: Asrar Alahmadi
- Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
Sponsor: Ohio State University Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202519 payments$15,011openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year20252 payments
- Rigel Pharmaceuticals, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.3%Kinase inhibitor33.3%Tagrisso61%Alecensa39%Part D<11 patientsMetabolism & gastrointestinal
25.3%Proton pump inhibitor13.1%Omeprazole100%Part D≥11 patientsCorticosteroid12.1%Prednisone100%Part D<11 patientsSensory organs
22.2%Corticosteroid22.2%Dexamethasone100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Hepatobiliary Progenitor-like Reprogramming in Liver Metastases
bioRxiv (Cold Spring Harbor Laboratory)
2026 - Trends in Mesothelioma Mortality in the United States Between 1999 and 2020
JTO Clinical and Research Reports
2025 - CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ricardo Carrau, MD
The Ohio State University Comprehensive Cancer Center
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD, PhD
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD
The Ohio State University Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”